Spacer-Containing Nucleic Acid Molecules for AAV Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Parvoviral gene therapy vectors, such as those based on adeno-associated virus (AAV), face safety issues due to contaminating nucleic acids like prokaryotic nucleic acids, antibiotic resistance genes, and nucleic acids with high CpG content, limiting the tolerable dose for effective treatments.
Innovation Solution
Incorporation of spacers flanking inverted terminal repeats (ITRs) in nucleic acid molecules to reduce the packaging of contaminating nucleic acids, using spacers that are eukaryotic in origin and devoid of prokaryotic elements, along with heterologous polynucleotides and promoters, to minimize the inclusion of undesirable nucleic acids in viral particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If spacers are incorporated into nucleic acid molecules to reduce contaminating nucleic acids, then the purity of viral particles is improved, but the device complexity increases
Solution Approach 1:
The nucleic acid molecule is segmented into distinct functional regions: spacers (SS1, SS2) at the terminals, inverted terminal repeats (ITR1, ITR2) for viral packaging, cloning sites (CS) for insertional flexibility, and heterologous polynucleotide molecules (HPM) for therapeutic function. This segmentation allows each component to perform its specific role while collectively reducing contaminating nucleic acids through the spacer regions that prevent packaging of adjacent contaminant sequences.
2Reliability
If spacers flanking inverted terminal repeats are used to minimize contaminating nucleic acids, then the safety of gene therapy vectors is improved, but the manufacturing process becomes more complex
Solution Approach 1:
The spacers are incorporated into the nucleic acid molecule structure before viral particle assembly occurs. This preliminary inclusion of spacer sequences flanking the inverted terminal repeats proactively prevents the packaging of contaminating nucleic acids during the viral particle formation process, rather than attempting to remove contaminants after assembly. The spacers act as protective barriers that are already in place during manufacturing.
3Object-affected harmful factors
If eukaryotic spacers devoid of prokaryotic elements are incorporated, then the immunogenicity of viral particles is reduced, but the nucleic acid molecule length increases
Solution Approach 1:
The spacers are designed with specific parameter characteristics: they are derived from eukaryotic sources (such as human or mouse genomic sequences) and explicitly exclude prokaryotic elements, antibiotic resistance genes, and sequences with high CpG content. This parameter selection changes the immunogenicity profile of the viral particles by removing immunostimulatory elements while maintaining the necessary functional length for safe packaging and expression.
Data Source
AI summary
The present invention relates to nucleic acid molecules containing spacers and methods of using the same.